JCRファーマ(4552.T): 社長スモール。イズカーゴクローバル開発後のR&D費は想定より下がるかも
Report Coverage
- Broker
- Citi
- Region
- Japan
- Sector
- Healthcare & Biotech
- Report Type
- Company Report
- Primary Focus
- JBC platform pipeline and R&D cost outlook
Full Report Document Access
This page is a research report summary and access guidance page. If you are searching for Citi JCRファーマ(4552.T) research report PDF or the full report document, use the summary, coverage fields and related links to confirm relevance before requesting VIP access. Full PDF report access is available to VIP members after request confirmation; the PDF is not publicly displayed on this page.
Report Summary
Citi's flash note on JCR Pharmaceuticals (4552.T) highlights the company's J-Brain Cargo (JBC) drug delivery platform and pipeline including JR-171, JR-141, JR-441, and Givinostat. The report suggests that post-JBC global development, R&D spending may come in lower than market expectations. A 10-year DCF valuation with a WACC of 5.6% supports a target price of 540 yen.
Key Takeaways
- JCR Pharma's J-Brain Cargo (JBC) platform is a proprietary drug delivery technology targeting CNS diseases, with multiple candidates in the pipeline
- Post-JBC global development phase, R&D expenses are expected to decline below current consensus estimates
- Pipeline includes JR-171, JR-141, JR-441, and Givinostat across various therapeutic areas
- 10-year DCF model with WACC of 5.6% yields a target price of 540 yen versus a current price around 466 yen
- CEO participated in a small-cap conference presentation highlighting company strategy and development milestones
Why This Report Matters
JCR Pharma's JBC platform offers differentiated CNS drug delivery capability, and the anticipated decline in R&D spending post-global development could meaningfully improve free cash flow and profitability.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Citi JCRファーマ(4552.T) report. It helps users review JCRファーマ(4552.T): 社長スモール。イズカーゴクローバル開発後のR&D費は想定より下がるかも coverage, key takeaways, and related broker or sector research paths across J-Brain Cargo drug delivery platform, CNS disease pipeline development, Post-development R&D cost reduction; JCR Pharmaceuticals, Acumen Pharmaceuticals.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.